TABLE 4.
MIP-1β and I-309 but not SDF-1α inhibit infection of human thymocytes with HIV-1Ba-La
| Expt. | Chemokine | Dose (μg/ml) | Mean p24 concn (ng/ml) | % Inhibition |
|---|---|---|---|---|
| I | None | 29.4 ± 1.1 | ||
| MIP-1β | 0.1 | 1.8 ± 0.2 | 99 | |
| I-309 | 0.1 | 14.3 ± 0.6 | 40 | |
| SDF-1α | 0.1 | 27.2 ± 1.5 | 0 | |
| II | None | 187.8 ± 20.0 | ||
| MIP-1β | 1.0 | 12.4 ± 1.1 | 93 | |
| 0.1 | 22.6 ± 2.2 | 88 | ||
| I-309 | 1.0 | 136.0 ± 8.3 | 27 | |
| 0.1 | 192.0 ± 12.5 | 0 | ||
| SDF-1 | 1.0 | 223.4 ± 18.6 | 0 | |
| III | None | 612.7 ± 21.7 | ||
| MIP-1β | 0.1 | 18.2 ± 3.3 | 97 | |
| I-309 | 0.1 | 387.3 ± 22.3 | 57 | |
| MIP-1β + I-309 | 0.1 + 0.1 | 38.7 ± 2.0 | 94 | |
| MIP-1β | 0.01 | 415.2 ± 34.7 | 32 | |
| I-309 | 0.01 | 265.1 ± 18.9 | 37 | |
| MIP-1β + I-309 | 0.01 + 0.01 | 246.2 ± 18.9 | 60 |
a
CD4 SP thymocytes were infected with HIV-1Ba-L (MOI, 0.01). Supernatants were harvested on day 6 for experiments 1 and 2 and on day 7 for experiment 3. Chemokine treatment and p24 analyses were performed as described in Table 3, footnote a.